LivaNova (LIVN) Total Debt Growth (1y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 157.11% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | -12.26% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 5.50% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | -2.48% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 0.12% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 8.70% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | - |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 15.70% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | -5.48% |
| 10 | LivaNova | 4.03 Bn | 3.45 Bn | 243.75 Mn | -54.23% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -54.23% |
| Dec 31, 2025 | -39.99% |
| Sep 30, 2025 | -30.62% |
| Jun 30, 2025 | -36.54% |
| Mar 31, 2025 | 0.69% |
| Dec 31, 2024 | 6.98% |
| Sep 30, 2024 | 6.65% |
| Jun 30, 2024 | 6.50% |
| Mar 31, 2024 | 15.11% |
| Dec 31, 2023 | 8.34% |
| Sep 30, 2023 | 8.75% |
| Jun 30, 2023 | 25.96% |
| Mar 31, 2023 | 18.52% |
| Dec 31, 2022 | 180.63% |
| Sep 30, 2022 | 232.92% |
| Jun 30, 2022 | -23.08% |
| Mar 31, 2022 | -30.45% |
| Dec 31, 2021 | -70.57% |
| Sep 30, 2021 | -75.09% |
| Jun 30, 2021 | -6.30% |
| Mar 31, 2021 | 22.14% |
| Dec 31, 2020 | 94.13% |
| Sep 30, 2020 | 90.56% |
| Jun 30, 2020 | 204.87% |
| Mar 31, 2020 | 197.24% |
| Dec 31, 2019 | 100.63% |
| Sep 30, 2019 | 117.52% |
| Jun 30, 2019 | 31.74% |
| Mar 31, 2019 | -1.13% |
| Dec 31, 2018 | 15.30% |
| Sep 30, 2018 | 26.75% |
| Jun 30, 2018 | 28.27% |
| Mar 31, 2018 | 50.88% |
| Dec 31, 2017 | 18.82% |
| Sep 30, 2017 | -14.27% |
| Jun 30, 2017 | -17.50% |
| Mar 31, 2017 | -29.18% |
| Dec 31, 2016 | -29.51% |